Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy.

ABSTRACT:

Introduction

Despite the recognized importance of atrophy in multiple sclerosis (MS), methods for its quantification have been mostly restricted to the research domain. Recently, a CE labelled and FDA approved MS-specific atrophy quantification method, MSmetrix, has become commercially available. Here we perform a validation of MSmetrix against established methods in simulated and in vivo MRI data.

Methods

Whole-brain and gray matter (GM) volume were measured with the cross-sectional pipeline of MSmetrix and compared to the outcomes of FreeSurfer (cross-sectional pipeline), SIENAX and SPM. For this comparison we investigated 20 simulated brain images, as well as in vivo data from 100 MS patients and 20 matched healthy controls. In fifty of the MS patients a sec

SUBMITTER: Steenwijk MD 

PROVIDER: S-EPMC5540882 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature